{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:44:36Z","timestamp":1761561876801},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2001,4,1]],"date-time":"2001-04-01T00:00:00Z","timestamp":986083200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Aging Clin Exp Res"],"published-print":{"date-parts":[[2001,4]]},"DOI":"10.1007\/bf03351533","type":"journal-article","created":{"date-parts":[[2014,6,10]],"date-time":"2014-06-10T16:55:42Z","timestamp":1402419342000},"page":"112-121","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["A multicenter, randomized, controlled trial to evaluate the safety profile, tolerability, and efficacy of rofecoxib in advanced elderly patients with osteoarthritis"],"prefix":"10.1007","volume":"13","author":[{"given":"K. E.","family":"Truitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. S.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"W. H.","family":"Ettinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Greenwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"DeTora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ehrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,7]]},"reference":[{"key":"BF03351533_CR1","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0160-3450(15)30253-1","volume":"NS34","author":"B Flynn","year":"1994","unstructured":"Flynn B.: Rheumatoid arthritis and osteoarthritis. Current and future therapies. Am. Pharm. NS34: 31\u201342, 1994.","journal-title":"Am. Pharm."},{"key":"BF03351533_CR2","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/art.1780280613","volume":"28","author":"C Baum","year":"1985","unstructured":"Baum C., Kennedy D.L., Forbes M.B.: Utilization of non steroidal antiinflammatory drugs. Arthritis Rheum. 28: 686\u2013692, 1985.","journal-title":"Arthritis Rheum."},{"key":"BF03351533_CR3","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0749-0690(18)30623-2","volume":"6","author":"MD Murray","year":"1990","unstructured":"Murray M.D., Brater D.C.: Nonsteroidal anti-inflammatory drugs. Clin. Geriatr. Med. 6: 365\u2013441, 1990.","journal-title":"Clin. Geriatr. Med."},{"key":"BF03351533_CR4","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","volume":"340","author":"MM Wolfe","year":"1999","unstructured":"Wolfe M.M., Lichtenstein D.R., Gurkirpal S.: Medical progress - Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 340: 1888\u20131897, 1999.","journal-title":"N. Engl. J. Med."},{"key":"BF03351533_CR5","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2165\/00002512-199710020-00005","volume":"10","author":"AC Phillips","year":"1997","unstructured":"Phillips A.C., Polisson R.P., Simon L.S.: NSAIDs and the elderly: toxicity and economic implications. Drugs & Aging 10: 119\u2013129, 1997.","journal-title":"Drugs & Aging"},{"key":"BF03351533_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/1529-0131(200005)43:5<978::AID-ANR4>3.0.CO;2-0","volume":"43","author":"GW Cannon","year":"2000","unstructured":"Cannon G.W., Caldwell J.R., Holt P., McLean B., Seidenberg B., Bolognese J., Ehrich E., Mukhopadhyay S., Daniels B., for the Rofecoxib Phase III Protocol 035 Study Group: Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum. 43: 978\u2013987, 2000.","journal-title":"Arthritis Rheum."},{"key":"BF03351533_CR7","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1001\/archinte.160.12.1781","volume":"160","author":"R Day","year":"2000","unstructured":"Day R., Morrison B., Luza A., Casteneda O., Strusberg A., Nahir M., Helgetveit K.B., Kress B., Daniels B., Bolognese J., Krupa D., Seidenberg B., Elliot E., for the Rofecoxib\/Ibuprofen Comparator Study Group:. A Randomized Trial of the Efficacy and Tolerability of the COX-2 Inhibitor Rofecoxib vs Ibuprofen in Patients with Osteoarthritis. Arch. Intern. Med. 160: 1781\u20131787, 2000.","journal-title":"Arch. Intern. Med."},{"key":"BF03351533_CR8","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1046\/j.1365-2036.1999.00529.x","volume":"13","author":"FL Lanza","year":"1999","unstructured":"Lanza F.L., Rack M.L., Simon T.J., Quan H., Bolognese J.A., Hoover M.E.: Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment. Pharmacol. Ther. 13: 761\u2013767, 1999.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"BF03351533_CR9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","volume":"117","author":"L Laine","year":"1999","unstructured":"Laine L., Harper S., Simon T., Bath R., Johanson J., Schwartz H., Stern S., Quan H., Bolognese J., for the Rofecoxib Osteoarthritis Endoscopy Study Group: A randomized trial comparing the effect of rofecoxib, a COX-2 specific inhibitor, to ibuprofen on the gastroduodenal mucosa of osteoarthritis patients. Gastroenterology 117: 776\u2013783, 1999.","journal-title":"Gastroenterology"},{"key":"BF03351533_CR10","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","volume":"282","author":"MJ Langman","year":"1999","unstructured":"Langman M.J., Jensen D.M., Watson D.J., Harper S.E., Zhao P.L., Quan H., Bolognese J.A., Simaon T.J.: Incidence of Upper Gastrointestinal Perforations, Symptomatic Ulcers, Bleeding (PUBs). Rofecoxib Compared to NSAIDs.JAMA 282: 1929\u20131933, 1999.","journal-title":"JAMA"},{"key":"BF03351533_CR11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/1529-0131(200002)43:2<370::AID-ANR17>3.0.CO;2-D","volume":"43","author":"C Hawkey","year":"2000","unstructured":"Hawkey C., Laine L., Simon T., Beaulieu A., Maldonado-Cocco J., Acevedo E., Shahane A., Quan H., Bolognese J., Mortensen E., for the Rofecoxib Osteoarthritis Endoscopy Multinational Study Group: Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. A randomized, controlled, double-blind, placebo-controlled trial. Arthritis Rheum. 43: 370\u2013377, 2000.","journal-title":"Arthritis Rheum."},{"key":"BF03351533_CR12","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1136\/gut.47.4.527","volume":"47","author":"G Sigthorsson","year":"2000","unstructured":"Sigthorsson G., Crane R., Simon T., Hoover M., Quan H., Bolognese J., Bjarnason I.: COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 47: 527\u2013532, 2000.","journal-title":"Gut"},{"key":"BF03351533_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0002-9343(00)00470-8","volume":"109","author":"RH Hunt","year":"2000","unstructured":"Hunt R.H., Bowen B., Mortensen E.R., Simon T.J., James C., Cagliola A., Quan H., Bolognese J.A.:A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am. J. Med. 109: 201\u2013206, 2000.","journal-title":"Am. J. Med."},{"key":"BF03351533_CR14","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., for the VIGOR Study Group: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N. Engl. J. Med. 343: 1520\u20131528, 2000.","journal-title":"N. Engl. J. Med."},{"key":"BF03351533_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein M.F.: Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12: 189\u2013198, 1975.","journal-title":"J. Psychiatr. Res."},{"key":"BF03351533_CR16","first-page":"1833","volume":"15","author":"N Bellamy","year":"1988","unstructured":"Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.: Validation study of WOMAC: A health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 15: 1833\u20131840, 1988.","journal-title":"J. Rheumatol."},{"key":"BF03351533_CR17","doi-asserted-by":"publisher","first-page":"19S","DOI":"10.1016\/0002-9343(93)90392-3","volume":"95","author":"GJ Morgan","year":"1993","unstructured":"Morgan G.J., Poland M., DeLapp R.E.: Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am. J. Med. 95: 19S\u201327S, 1993.","journal-title":"Am. J. Med."},{"issue":"5","key":"BF03351533_CR18","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2165\/00003495-199000405-00015","volume":"40","author":"P Munzel","year":"1990","unstructured":"Munzel P., Lemmel E.E.: Efficacy and safety of nabumetone in 4,541 elderly patients from a drug monitoring study. Drugs 40 (Suppl. 5): 62\u201364, 1990.","journal-title":"Drugs"},{"key":"BF03351533_CR19","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1001\/archinte.1993.00410220073008","volume":"153","author":"SH Roth","year":"1993","unstructured":"Roth S.H., Tindall E.A., Jain A.K., McMahon G., April P.A., Bockow B.I., Cohen S.B., Fleishmann R.M.:A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch. Intern. Med. 153: 2565\u20132571, 1993.","journal-title":"Arch. Intern. Med."},{"key":"BF03351533_CR20","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1001\/archinte.1993.00410020091008","volume":"153","author":"PA Rochon","year":"1993","unstructured":"Rochon P.A., Fortin P.R., Dear K.B.G., Minaker K.L., Chalmers T.C.: Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch. Intern. Med. 153: 243\u2013248, 1993.","journal-title":"Arch. Intern. Med."},{"key":"BF03351533_CR21","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/ard.56.10.578","volume":"56","author":"D Hamerman","year":"1997","unstructured":"Hamerman D.: Aging and the musculoskeletal system. Ann. Rheum. Dis. 56: 578\u2013585, 1997.","journal-title":"Ann. Rheum. Dis."},{"key":"BF03351533_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1001\/archinte.160.7.913","volume":"160","author":"PE Lipsky","year":"2000","unstructured":"Lipsky P.E., Brooks P., Crofford L.J., Du Bois R., Graham D., Simon L.S., van de Putte L.B., Abramson S.B.: Unresolved issuesinthe role of cyclooxygenase-2in normal physiologic processes and disease. Arch. Intern. Med. 160: 913\u2013920, 2000.","journal-title":"Arch. Intern. Med."},{"key":"BF03351533_CR23","doi-asserted-by":"publisher","first-page":"PII","DOI":"10.1016\/S0009-9236(99)80184-2","volume":"65","author":"HE Greenberg","year":"1999","unstructured":"Greenberg H.E., Gillen L.P., Dorval E.P., Huntington M., Wong P., Wildonger L., Larson P., Gottesdiener K.M., Waldman S.A.: MK-0966, a cyclooxygenase inhibitor, has no effect on the anti-platelet activities of low-dose aspirin, measured by serum thromboxane B2 and platelet aggregation. Clin. Pharm. Therapeut. 65: Abstract PII\u201366, 1999.","journal-title":"Clin. Pharm. Therapeut."},{"key":"BF03351533_CR24","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1002\/j.1552-4604.1991.tb03743.x","volume":"31","author":"A Whelton","year":"1991","unstructured":"Whelton A., Hamilton C.W.: Nonsteroidal anti-inflammatory drugs: effects on kidney function. J. Clin. Pharmacol. 31: 588\u2013598, 1991.","journal-title":"J. Clin. Pharmacol."},{"key":"BF03351533_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1023\/A:1008288532636","volume":"7","author":"JG Ruiz","year":"1997","unstructured":"Ruiz J.G., Lowenthal D.T.: NSAIDs and nephrotoxicity in the elderly. Geriatr. Nephrol. Urol. 7: 51\u201357, 1997.","journal-title":"Geriatr. Nephrol. Urol."},{"key":"BF03351533_CR26","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2165\/00003495-199651020-00001","volume":"51","author":"PW Leeuw de","year":"1996","unstructured":"de Leeuw P.W.: Nonsteroidal Anti-inflammatory Drugs and Hypertension - The Risks in Perspective. Drugs 51: 179\u2013187, 1996.","journal-title":"Drugs"},{"key":"BF03351533_CR27","doi-asserted-by":"publisher","first-page":"65S","DOI":"10.1016\/S0002-9343(99)00369-1","volume":"107","author":"DC Brater","year":"1999","unstructured":"Brater D.C.: Effects of Nonsteroidal Anti-inflammatory Drugs of Renal function: Focus of Cyclooxygenase-2-Selective Inhibition. Am. J. Med. 107: 65S\u201371S, 1999.","journal-title":"Am. J. Med."},{"key":"BF03351533_CR28","doi-asserted-by":"publisher","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","volume":"121","author":"AG Johnson","year":"1994","unstructured":"Johnson A.G., Nguyen T.V., Dayai R.O.: Do nonsteroidal antiinflammatory drugs affect blood pressure? Ann. Intern. Med. 121: 289\u2013300, 1994.","journal-title":"Ann. Intern. Med."},{"key":"BF03351533_CR29","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1172\/JCI108470","volume":"58","author":"JC Romero","year":"1976","unstructured":"Romero J.C., Dunlap C.L., Strong C.G.: The effect of indomethacin and other anti-inflammatory drugs on the reninangiotensin system. J. Clin. Invest. 58: 282\u2013288, 1976.","journal-title":"J. Clin. Invest."},{"key":"BF03351533_CR30","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1001\/archinte.1990.00390140024006","volume":"150","author":"MT Stillman","year":"1990","unstructured":"Stillman M.T., Schlesinger P.A.: Nonsteroidal anti-inflammatory drug nephrotoxicity. Should we be concerned? Arch. Intern. Med. 150: 268\u2013270, 1990.","journal-title":"Arch. Intern. Med."}],"container-title":["Aging Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03351533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03351533\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03351533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03351533.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,18]],"date-time":"2020-02-18T01:14:52Z","timestamp":1581988492000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03351533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,4]]}},"alternative-id":["BF03351533"],"URL":"https:\/\/doi.org\/10.1007\/bf03351533","relation":{},"ISSN":["1594-0667","1720-8319"],"issn-type":[{"value":"1594-0667","type":"print"},{"value":"1720-8319","type":"electronic"}],"subject":[],"published":{"date-parts":[[2001,4]]},"assertion":[{"value":"6 October 2000","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2001","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}